Price Chart

Profile

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer’s. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
URL https://www.igcinc.us
Investor Relations URL N/A
HQ State/Province Maryland
Sector Health Care
Industry Pharmaceuticals
Equity Style Small Cap/Value
Next Earnings Release Nov. 13, 2024 (est.)
Last Earnings Release Aug. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer’s. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
URL https://www.igcinc.us
Investor Relations URL N/A
HQ State/Province Maryland
Sector Health Care
Industry Pharmaceuticals
Equity Style Small Cap/Value
Next Earnings Release Nov. 13, 2024 (est.)
Last Earnings Release Aug. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A